Skip to main content

IgA Nephropathy clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for
  • Atrasentan in Patients With IgA Nephropathy

    Sorry, in progress, not accepting new patients

    The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

    San Francisco, California and other locations

  • Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

    Sorry, not yet accepting patients

    The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.

    San Francisco, California and other locations

Last updated: